EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Age on Early CAR T‐Cell Therapy Toxicity: A Propensity Score Matching Analysis

Jia Yi Tan iD, Yong-Hao Yeo iD, Qi Xuan Ang iD, George Chen iD, Kok Hoe Chan iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jia Yi Tan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite the growing use of CAR‐T therapy, adults over 65 still receive this treatment less frequently than younger patients.

Methods

Using the Nationwide Readmissions Database (2018–2020), we analyzed 2928 CAR‐T recipients, dividing them into young (18–40), middle‐aged (41–65), and older adults (≥ 66). Propensity score matching (caliper of 0.2, 1:1:1 ratio) was performed. We adjusted for the following confounding variables: gender, comorbidities, and social factors including smoking, alcohol use, and illicit drug use.

Results

Older adults had the highest rates of acute kidney injury (11.7% vs. 13.0% vs. 18.1%, p = 0.02) and cardiac complications (2.0% vs. 3.6% vs. 5.4%, p = 0.03). These three different age groups had comparable rates of leukopenia (45.0% vs. 42.7% vs. 39.1%, p = 0.10), infection (41.0% vs. 43.6% vs. 42.1%, p = 0.74), neurotoxicity (6.2% vs. 6.5% vs. 7.7%, p = 0.52), and pulmonary embolism (1.0% vs. 2.9% vs. 2.3%; p = 0.2). Despite the highest rates of non‐home discharge among the older patients (14.0% vs. 7.5% vs. 8.8%), there were no significant differences in early mortality (5.2% vs. 6.2% vs. 6.7%, p = 0.34), 30‐day readmission (23.1% vs. 23.8% vs. 24.4%, p = 0.48), prolonged index hospitalization (96.1% vs. 94.8% vs. 93.6%, p = 0.14), and total length of stay (21.2 days vs. 18.2 days vs. 21.3 days, p = 0.58).

Conclusion

CAR‐T therapy is safe among older adults with close monitoring for cardiac and renal complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveNeoplasmsHumansMaleFemaleMiddle AgedPropensity ScoreAdultAgedAge FactorsYoung AdultAdolescentPatient ReadmissionAcute Kidney InjuryRetrospective Studies

Stichwörter der Autor:innen

CAR T therapychimeric antigen receptorhematologyoncologyoutcomes

Autor:innen und Institutionen

  • Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.
  • Department of Internal Medicine/Pediatrics, Beaumont Health, Royal Oak, Michigan, USA.
  • Department of Internal Medicine, Sparrow Health System and Michigan State University, East Lansing, Michigan, USA.
  • MD Anderson Cancer Center, Houston, Texas, USA.
  • Charleston Area Medical Center, Charleston, West Virginia, USA.

ORCID-Profile: Jia Yi Tan, Yong-Hao Yeo, Qi Xuan Ang, George Chen, Kok Hoe Chan

Zitieren

APA

Tan, J. Y., Yeo, Y. H., Ang, Q. X., Chen, G., & Chan, K. H. (2025). Impact of Age on Early CAR T‐Cell Therapy Toxicity: A Propensity Score Matching Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.71344

Vancouver

Tan JY, Yeo YH, Ang QX, Chen G, Chan KH. Impact of Age on Early CAR T‐Cell Therapy Toxicity: A Propensity Score Matching Analysis. Cancer Medicine. 2025. doi:10.1002/cam4.71344

BibTeX
@article{Tan2025,
  author = {Tan, Jia Yi and Yeo, Yong-Hao and Ang, Qi Xuan and Chen, George and Chan, Kok Hoe},
  title = {Impact of Age on Early CAR T‐Cell Therapy Toxicity: A Propensity Score Matching Analysis},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71344}
}
Kostenlos starten →